hrp0092p1-405 | Pituitary, Neuroendocrinology and Puberty (2) | ESPE2019

Metabolic Changes in Children Treated for Medulloblastoma

Kalinin Alexey , Strebkova Natalia , Vasyukova Olga , Okorokov Pavel , Zheludkova Olga

Abstract: The development of endocrine disorders after complex treatment of medulloblastoma is out of doubt. Much less attention is paid to the study of metabolic changes in the outcome of treatment. In our clinic, we examined 63 patients (40 males/23 females) after the complex therapy of medulloblastoma (surgery, craniospinal radiation therapy and chemotherapy). Patients had a median age (range) of 11.3 (5.5÷17.9) years. They were treated for medulloblas...

hrp0092p3-55 | Diabetes and Insulin | ESPE2019

The Role of Patient Adherence to Insulin Pump Therapy with Long-Term Treatment of Type 1 Diabetes

Turkunova Mariia , Bashnina Elena , Tsargasova Irina , Klitsenko Olga , Berseneva Olga

Background: Insulin pumps are widely used in the treatment of type 1 diabetes mellitus (T1D) in children because of numbers of advantages in compare with multiple daily insulin injections (MDI). However, the long-term efficacy of continuous subcutaneous insulin infusion therapy (CSII) in achieving and maintaining of diabet stability is still not resolved.Purpose: Determine the feffectiveness-related factors of glycemic c...

hrp0082p1-d2-256 | Thyroid (1) | ESPE2014

Screening for Congenital Hypothyroidism in the Russian Federation (1997–2012)

Bezlepkina Olga , Chikulaeva Olga , Chumakova Olga , Karavaeva Lyudmila , Bezlepkin Alexey , Peterkova Valentina

Background: Screening for congenital hypothyroidism (CH) in the Russian Federation started in 1994. A survey was conducted in 1994 on the basis of 32 laboratories, and since 2007 newborn screening is being carried out in 79 laboratories of 83 regions of the Russian Federation.Objective and hypotheses: To study the prevalence of CH in Russia and in different regions of the Russian Federation.Method: Official statistics on CH screeni...

hrp0089p3-p315 | Pituitary, Neuroendocrinology and Puberty P3 | ESPE2018

The Change in Growth’s Velocity in Patients with Premature Puberty Receiving Treatment with Analogues of Lyuliberin

Berseneva Olga , Bashnina Elena , Turkunova Mariia

Background: Suppression of hypothalamic-pituitary-gonadal system activity by luliberin analogues in premature sexual development of the central genesis is accompanied by a decrease in growth’s velocity, sexual development and progression of bone age.Aim: Study of the effectiveness of gonadotropin-releasing hormone agonist therapy, their influence on the physical developmentMethods: 66 patients were treated by triptorelin. Idio...

hrp0086p2-p541 | Fat Metabolism and Obesity P2 | ESPE2016

Non-Medicament Treatment of Severe Obese Children, Using the One-Year Courses

Zagrebaeva Olga , Solntsava Anzhalika , Yemelyantsava Tatsiana

Background: It is hard to treat severe obese children only with diet and physical activity, psychological interventions are need.Objective and hypotheses: To examine the differences between courses of non-medicament treatment of severe obese children.Method: We examined 32 pubertal severe obese children BMI 31.2±0.8 kg/m2, 13.5±0.3 years. The newel (in Belarus) course of non-medicament treatment of obesity (die...

hrp0086p2-p684 | Growth P2 | ESPE2016

Growth Effects of Somatropin during the Treatment Congenital Hypopituitarism in Children after the Start of Puberty

Berseneva Olga , Bashnina Elena , Turkunova Maria

Background: Today the features of GH therapy in children after reaching the beginning of puberty and the necessity of therapy in such age group are discussed.Objective and hypotheses: To identify the relationship between the growth increase after the start of puberty (patient’s bone age achieved 12–13 years, according to the atlas Greulich) and the individual characteristics of the patients.Method: Thirty-four patients wi...

hrp0082p3-d2-780 | Fat Metabolism & Obesity (1) | ESPE2014

Age-Related Characteristics of Nutritional Status in Children with Alimentary Obesity

Volkova Nataliya , Solntsava Anzhalika , Zagrebaeva Olga

Background: Among alimentary factors leading to obesity in children, the main ones are: consumption of high-calorie foods with high content of carbohydrates and getting more calories during the second half of the day.Objective: To study feeding habits in children of different ages with alimentary obesity compared with normative values.Methods: We compared 3-day food diaries of 115 children with alimentary obesity with nutritional s...

hrp0084p2-258 | Diabetes | ESPE2015

Cardiac Autonomic Neuropathy is Highly Predictive for Survival in Children with Mauriac Syndrome

Arshinkova Margarita , Slavcheva Olga , Konstantinova Maia

Background: Diabetic autonomic neuropathy (DAN) is predictive for subsequent mortality mainly due to terminal renal insufficiency. DAN is screened by cardiac tests based on heart rate variability (HRV).Aim: To assess cardiac autonomic neuropathy (CAN) and its predictive value for survival in children with Mauriac syndrome.Material and methods: The study included 12 patients with Mauriac syndrome (growth retardation, hepatomegaly an...

hrp0084p3-814 | Endocrine Oncology | ESPE2015

Results of GH Treatment in Childhood Brain Tumours Survivors

Mazerkina Nadia , Gorelyshev Sergey , Geludkova Olga

Background: GH deficiency is the most common endocrine disorder in childhood brain tumours survivors.Objective and hypotheses: To examine results and safety of GH treatment in patients with childhood brain tumours.Method: 118 patients (72 craniopharyngioma, 29 medulloblastoma, 17 germ cell tumours) received hGH in the dose 0.03–0.034 mg/kg per day for 2.3±0.8 years. The mean chronological age at the start of the treatment...

hrp0084p3-980 | GH & IGF | ESPE2015

Final Height in Patients with Isolated GH Deficiency and Multiple Pituitary Hormone Deficiencies, Treated with GH

Bashnina Elena , Berseneva Olga , Fogt Sergey

Background: To date a lot of data on the efficacy of GH treatment of children with short stature was accumulated. GH is the major but not exclusive endocrine regulator of linear growth. Influence of multiple pituitary hormone deficiencies on the final growth remains poorly understood.Aim: To compare the results of treatment with GH in patients with isolated GH deficiency and multiple pituitary hormone deficiencies.Methods: 15 patie...